Mumbai, Feb. 3 -- However, revenue from operations was at Rs 1,692.74 crore in the third quarter of FY25, up 3.81% year on year (YoY).

Profit before tax was at Rs 177.78 crore in Q3 FY25, down 3.68% from Rs 184.58 crore in Q3 FY24.

EBITDA increased by 1% to Rs 271 crore, with an EBITDA margin of 16% in Q3 FY25.

On the segmental front, API revenue was Rs 259 crore (down 10% YoY). In the Formulations business, US revenue was Rs 521 crore (up 10% YoY), India revenue was Rs 614 crore (up 3% YoY) and Ex-US revenue was Rs 299 crore (up 10% YoY).

US Generics reported a 10% year-on-year growth, driven by the ramp-up of key launches and market share gains in several existing products. New launches are expected to drive further growth in the up...